Oxodipine |
Catalog No.GC28261
One-Click Copy Product Info
|
Oxodipine, a dihydropyridine-type calcium antagonist , inhibited KCl-induced aortic contraction in rabbits and reduced cardiac force in less potent rat ventricular test-paper contractions.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 90729-41-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Oxodipine, a dihydropyridine-type calcium antagonist , inhibited KCl-induced aortic contraction in rabbits and reduced cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduced L-type Ca currents (I) with an IC of 0.24 μM, and against T-type Ca currents (I) with an IC of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs.
In aortic rings, Oxodipine (10(-11)-10(-6) M) inhibited in a concentration-dependent manner the contractions induced by high K+ (IC50 = 9.0 +/- 4.0 x 10(-10) M) or by Ca2+ in high K+ solution (IC50 = 6.2 +/- 2.4 x 10(-9) M). In mesenteric resistance vessels, Oxodipine inhibited the contractions induced by high K+(IC50 = 5.2 +/- 3.1 x 10(-10)).[4]
Oxodipine (5, 20, and 50 μg/kg; anesthetized dogs), a new dihydropyridine calcium channel blocker, ineffective at 5 μg/kg, whereas doses of 20 and 50 μg/kg of oxodipine elicited a decrease in blood pressure with no change in heart rate. These Result suggest that, in contrast to other first-generation dihydropyridines, oxodipine exerts a relatively specific action on blood vessels without significant intrinsic negative chronotropic properties in anesthetized sinoaortic-denervated dogs.[4]
References:
1.Tamargo J, et al. Effects of oxodipine on 45Ca movements and contractile responses in vascular smooth muscle. Br J Pharmacol. 1989;97(2):339-346.
2.Galán L, et al. Characteristics of Ca2+ channel blockade by oxodipine and elgodipine in rat cardiomyocytes. Eur J Pharmacol. 1998;357(1):93-105.
3.Egros F, et al. An original intragastric delivery system for oral administration of solid formulations to fully conscious rats: its application to oxodipine studies. Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:71-76.
4.Montastruc P, et al. Effect of oxodipine, a novel dihydropyridine calcium channel blocker, in neurogenic hypertensive dogs. Arch Int Pharmacodyn Ther. 1993;321:57-62.
| Cas No. | 90729-41-2 | SDF | |
| Formula | C19H21NO6 | M.Wt | 359.3731 |
| Solubility | DMSO: 100.00 mg/mL (278.26 mM), Sonication is recommended. | Storage | -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7826 mL | 13.9131 mL | 27.8262 mL |
| 5 mM | 556.5 μL | 2.7826 mL | 5.5652 mL |
| 10 mM | 278.3 μL | 1.3913 mL | 2.7826 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)